Skip to main content
. 2010 Nov 26;300(2):H555–H564. doi: 10.1152/ajpheart.00847.2010

Fig. 7.

Fig. 7.

MAP in response to ganglionic blockade with hexamethonium before Aldo or ANG II infusions were begun and on the last day of Aldo or ANG II infusion in all groups. #P < 0.05 compared with rats receiving central treatment with AT1R or MR antagonist (A), apocynin or tempol (B), and RU28318 (C).